araceli miranda

biologa

[soda_troubles, I have faith in Discord. @set_fortess]

Petri SLE Pearls: An Update
https://t.co/IJAWOwI9MS

[NDT @NDTsocial]

Complement activation in secondary thrombotic microangiopathies

https://t.co/ToT8JAMBFf

This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as a therapeutic strategy.

[Arkana Laboratories @arkanalabs]

Here is today’s #eyeSCANdy! Acellular SEM of membranous GN, stage IV. Note the distinct craters and circular orifices of the incompletely bridged reticular BM. Inset: TEM showing thickened GBM with discrete crater (arrow) and partially bridged and resorbed deposits.
Photo courtesy of Dr. Stephen Bonsib. #renal #pathology #kidneypath

[Jay R. Seltzer @jrseltzer]

Acanthocyte - darkfield illumination - from young woman presenting with acute respiratory failure, and AKI - #UrinarySediment #UrineMicroscopy

[ASN Publications @asnpublications]

The October issue of JASN is now available online! Topics covered include:
- Neutrophil Extracellular Traps in Complement-Mediated TMA
- Medications Influencing Cystatin C Level
- and more
https://t.co/VC4UodNa5I
#ASNJASN

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

Anti-nephrin antibodies disrupt slit diaphragm geometry, as revealed by cryo-electron tomography

🧐The cryo-ET–based findings suggest how antibody binding to nephrin can translate into podocyte architectural failure.

▶️https://t.co/UXH8emxR9m

[ASN Publications @asnpublications]

Can a kidney failure risk score (KFRE) help predict the risk of heart disease and death in people with chronic kidney disease? Read this article in #ASNKidney360 to find out. https://t.co/0PA6q8Oqh2

[Alí Duarte, MD @AliDuarteMD]

1/ SLE is not confined to young women. Across 6 CDC-supported, population-based lupus registries (including LUMEN💡)—we examined how SLE incidence varies across demographic groups in diverse U.S. populations.

https://t.co/vlwAcfAg3P

[Arkana Laboratories @arkanalabs]

This photomicrograph of a Jones silver stain is interesting in that it shows two findings. First, at 10 o’clock an area of hyalinosis at the perihilar region is present and compatible with perihilar focal segmental glomerulosclerosis. However, if you look closely you will notice that the podocyte cell bodies are very large and vacuolated. This finding is uncommon and is typically seen in the setting of Fabry disease (and usually very difficult to appreciate, unlike in this example). And, while myeloid bodies can be seen in patients on chloroquine or hydroxychloroquine therapy, they are typically sparse or focal in these settings. As suspected, extensive accumulation of intra-podocyte myeloid bodies (a.k.a. zebra bodies, myelinosomes) are seen in all podocyte cell bodies examined (see image below). And, subsequent testing revealed Fabry disease in this patient.
Interestingly, the perihilar focal segmental glomerulosclerosis identified here was present in numerous glomeruli as well as marked glomerulomegaly. While this patient was not obese nor had premature delivery at birth, the biopsy showed around 70% global sclerosis and a second diagnosis of hyperfiltration injury was rendered, likely due to acquired reduced nephron mass secondary to glomerular/nephron loss from the underlying Fabry disease.

#renalpath #kidneypath #pathology #renal #pathtwitter

[ManpowerGroup MeCCA @ManpowerMeCA]

✔️ Contar con las personas adecuadas en el momento oportuno puede marcar la diferencia para alcanzar tus objetivos.

Encuentra el #talento que necesitas, cuando lo necesitas.

👉 https://t.co/ttpRiI1gMd

#ManpowerGroupMX #TalentSolutions

[IMIN @IMINmx]

¿Cómo prevenir fracturas y enfermedad ósea en pacientes con ERC?

El Dr. Juan Carlos Ramírez Sandoval abordará este tema en Actualízame IMIN 2026.

💻 21 clases en línea
🏥 17 clases presenciales

https://t.co/YVp7oWmiMT

#ActualízameIMIN #ERC #Nefrología

[glomcon @GlomCon]

The GlomCon Hawaii 2026 abstracts are now published in Rare Kidney Diseases.

Explore the research presented at GlomCon Hawaii and review the latest findings in rare kidney and glomerular disease.

🔗 Read the abstracts: https://t.co/7a4Oycie6J

#GlomCon #GlomConHawaii #Nephrology #KidneyResearch #RareKidneyDiseases

[IMIN @IMINmx]

¡ESTAMOS A SOLO 3 DÍAS!

🩺 Te invitamos a una nueva sesión académica con el tema, Dispositivos inteligentes en nefrología intervencionista, de los datos a la toma de decisiones.

📅 Jueves 1 de octubre | 20:00 hrs.
🖥️ Acceso gratuito.

https://t.co/oFFc3LiE1U

#WebinarIMIN

[soda_troubles, I have faith in Discord. @set_fortess]

Predicting relapse and infection to optimize patient outcomes in ANCA-associated vasculitis: data from the MAINRITSAN trials cohort
https://t.co/ydD5ZMNtuI

[Jay R. Seltzer @jrseltzer]

Fibrin cast containing RBC's - brightfield with SM stain - from young woman presenting with acute respiratory failure, and AKI - #UrinarySediment #UrineMicroscopy

[Jay R. Seltzer @jrseltzer]

RBC cast under darkfield illumination - from young woman presenting with acute respiratory failure, and AKI - #UrinarySediment #UrineMicroscopy

[ASN Publications @asnpublications]

#Review in #ASNKidney360: Monoclonal gammopathy of renal significance (MGRS) can cause serious kidney injury even without overt cancer. Early diagnosis and clone-directed therapy are key, highlighting need for collaboration with nephrology, pathology, and hematology teams. https://t.co/OBiyDHTP3A

[ASN Publications @asnpublications]

Join the Best of ASN Journals session at #KidneyWk 2026 to hear journal editors highlight innovative clinical, translational, and basic science research published in JASN, CJASN, and Kidney360. Learn more: https://t.co/BKxOPB39Uf

[MaFer Zavala @Mafer_ZavalaM]

2/10
✅ Rituximab induces CR/PR in ~60% of patients with PMN by 24 months

➡️ Yet, incomplete depletion of tissue-resident memory B cells and the compensatory BAFF surge after rituximab may support the survival and re-emergence of autoreactive B-cell populations.

💡 The rationale: Continuing belimumab after rituximab blocks BAFF-mediated survival signals, potentially delaying B-cell reconstitution, favoring repopulation with naïve/transitional B cells, and maintaining suppression of memory B cells

[MaFer Zavala @Mafer_ZavalaM]

3/10
💻 Study design: Phase II, open-label, single-arm, multicenter prospective trial (10 US sites)

👥 Population :
- Adults with biopsy-confirmed anti-PLA2R–positive PMN
- Persistent nephrotic-range proteinuria ( despite maximal RAAS blockade)
- ⁠Preserved/moderately impaired renal function (high risk population )